Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis
Kuang-Yuh Chyu, … , Eun Ji Chung, Prediman K. Shah
Kuang-Yuh Chyu, … , Eun Ji Chung, Prediman K. Shah
Published May 10, 2022
Citation Information: JCI Insight. 2022;7(11):e149741. https://doi.org/10.1172/jci.insight.149741.
View: Text | PDF
Research Article Cardiology Vaccines

Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis

  • Text
  • PDF
Abstract

Active immunization with the apolipoprotein B-100 (ApoB-100) peptide P210 reduces experimental atherosclerosis. To advance this immunization strategy to future clinical testing, we explored the possibility of delivering P210 as an antigen using nanoparticles, given this approach has been used clinically. We first characterized the responses of T cells to P210 using PBMCs from patients with atherosclerotic cardiovascular disease (ASCVD). We then investigated the use of P210 in self-assembling peptide amphiphile micelles (P210-PAMs) as a vaccine formulation to reduce atherosclerosis in B6.129P2-Apoetm1Unc/J (ApoE–/–) mice and P210’s potential mechanisms of action. We also generated and characterized a humanized mouse model with chimeric HLA-A*02:01/Kb in ApoE–/– background to test the efficacy of P210-PAM immunization as a bridge to future clinical testing. P210 provoked T cell activation and memory response in PBMCs of patients with ASCVD. Dendritic cell uptake of P210-PAM and its costaining with MHC-I molecules supported its use as a vaccine formulation. In ApoE–/– mice, immunization with P210-PAMs dampened P210-specific CD4+ T cell proliferative response and CD8+ T cell cytolytic response, modulated macrophage phenotype, and significantly reduced aortic atherosclerosis. Potential clinical relevance of P210-PAM immunization was demonstrated by reduced atherosclerosis in the humanized ApoE–/– mouse model. Our data support experimental and translational use of P210-PAM as a potential vaccine candidate against human ASCVD.

Authors

Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Paul C. Dimayuga, Nicole W.M. Lio, Bojan Cercek, Noah T. Trac, Eun Ji Chung, Prediman K. Shah

×

Figure 5

P210-PAM immunization in ApoE–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
P210-PAM immunization in ApoE–/– mice.
(A–C) Immune regulatory profile o...
(A–C) Immune regulatory profile of CD4+ and (D and E) CD8+ T cells in splenocytes of immunized mice 1 week after second booster. (F and G) Splenic T cell proliferation of immunized mice in response to P210 peptide or (H and I) Concanavalin A (Con A) stimulation assessed by BrdU staining. (J) CD107a to assess CD8+ T cell cytolytic activity in splenocytes of immunized mice. (K) Representative photographs of aortic en face staining with oil red O at 25 weeks of age. (L) Atherosclerosis measured as percentage of whole aorta stained by oil red O. Splenic mRNA expression of (M) IL-1β, (N) IL-1R1, (O) IL-6, and (P) IL-17a. Number of mice used in each group is represented by the number of dots in individual figure. *P < 0.05; †P = 0.05, 2-tailed t test except for L, 1-way ANOVA with Holm-Šidák multiple comparisons test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts